DOCSLIB.ORG

Net Loss to Adjusted EBITDA: Non-GAAP Reconciliations Three Months Ended December 31 Year Ended December 31 $ in Thousands 2020 2019 2020 2019

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Net Loss to Adjusted EBITDA: Non-GAAP Reconciliations Three Months Ended December 31 Year Ended December 31 $ in Thousands 2020 2019 2020 2019 Nature Inspired. Technology Driven.™ FOURTH QUARTER 2020 FINANCIAL RESULTS CONFERENCE CALL, MARCH 4, 2021 © CALYXT, INC. ALL RIGHTS RESERVED Forward Looking Statements We have made these forward-looking statements in reliance on the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as “anticipates,” “believes,” “continue,” “estimates,” “expects,” “targets,” “intends,” “may,” “might,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” or the negative of these terms and other similar terminology. Forward-looking statements in this report include statements about the potential impact of the COVID-19 pandemic on our business and operating results; our future financial performance; product pipeline and development; our business model and strategies for commercialization and sales of commercial products; regulatory progression; potential collaborations, partnerships and licensing arrangements and their contribution to our financial results, cash usage, and growth strategies; and anticipated trends in our business. These and other forward-looking statements are predictions and projections about future events and trends based on our current expectations, objectives and intentions and premised on current assumptions. Our actual results, level of activity, performance, or achievements could be materially different than those expressed, implied, or anticipated by forward-looking statements due to a variety of factors, including, but not limited to: the severity and duration of the evolving COVID-19 pandemic and the resulting impact on macro-economic conditions; the impact of increased competition; disruptions at our key facilities; changes in customer preferences and market acceptance of our products; competition for collaboration partners and licensees and the successful execution of collaborations and licensing agreements; the impact of adverse events during development, including unsuccessful field trials or developments trials or disruptions in seed production; the impact of improper handling of our product candidates by unaffiliated third parties during development, such as the improper aerial spraying of our high fiber wheat product candidate; failures by third-party contractors; inaccurate demand forecasting; the effectiveness of commercialization efforts by commercial partners or licensees; our ability to make grain sales on terms acceptable to us; the timing of our grain sales; our ability to collect accounts receivable; disruptions to supply chains, including transportation and storage functions; commodity price conditions; the impact of changes or increases in oversight and regulation; disputes or challenges regarding intellectual property; proliferation and continuous evolution of new technologies; management changes; dislocations in the capital markets; and other important factors discussed in Part I, Item 1A, “Risk Factors” of this Annual Report on Form 10-K, which should be considered an integral part of Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” © CALYXT, INC. ALL RIGHTS RESERVED 2 Calyxt Executive Chair Yves Ribeill, Ph.D. Dr. Ribeill has served as a member of the Calyxt board since July 2018 and was Calyxt's interim Chief Executive Officer from August 2018 to October 2018. Since January 2018, he has served as the Chief Executive Officer of Ribogenics, Inc., which is a private biotechnology company working on RNA biology. Dr. Ribeill was also a founder of SCYNEXIS, Inc. (SCYX) and served as its Chief Executive Officer from November 1999 to April 2015. Dr. Ribeill has more than 35 years of experience in the healthcare industry, with an expertise in anti-infective diseases. Prior to moving to the U.S. 21 years ago, Dr. Ribeill held several management positions during his international career with Rhône-Poulenc and Aventis in France Yves Ribeill, Ph.D. and in the UK. Dr. Ribeill was a member of the Scientific Advisory Committee of the World Health Organization and the Medicines for Malaria Venture in Geneva. © CALYXT, INC. ALL RIGHTS RESERVED 3 Investment Highlights • Leveraging differentiated technology to develop product candidates including TALEN® gene-editing platform • First to bring gene-edited consumer trait to market 1 • Pipeline has total addressable market of $8.8 billion and is targeted at critical industry dynamics including consumer demand for specialty ingredients and supporting sustainability objectives • Capital-efficient business model with multiple routes to market for product candidates 1 See the information on slides 47-52 of Calyxt’s 2020 Virtual Investor Day on November 17, 2020 available on the Company’s website for sources and key assumptions underlying the total addressable market and potential product revenue opportunities, which includes information that was publicly disclosed as of November 17, 2020 and is not being updated as of the date of this presentation. © CALYXT, INC. ALL RIGHTS RESERVED 4 Q4 2020 Key Highlights • Continued development of key projects in oats and hemp, and carried on our development in soybean, extending our first-mover advantage in this broad-acre crop • Secured commitment from ADM (NYSE: ADM) to purchase all remaining 2019 grain inventory and 2020 grain production o Key step in Calyxt’s transition to advanced go-to-market strategies o Expected cumulative sales of over 4 million bushels o As of this date all 2019 grain inventory and 40 percent of 2020 grain production has been sold; sales will continue throughout 2021 • Executed commercial agreement with S&W Seed Company (NASDAQ: SANW) for the exclusive license of IQ™ Alfalfa seed in the U.S. and other select geographies • Capital raise completed, contributing to extension of cash runway into second half of 2022 © CALYXT, INC. ALL RIGHTS RESERVED 5 Early 2021 Subsequent Events • Entered into a soybean seed sale agreement with Perdue AgriBusiness • Yves Ribeill, Ph.D. named Executive Chairman, replacing CEO Jim Blome • Completed appointments of world-renowned plant- biochemistry experts to new Scientific Advisory Board o Dan Voytas, Ph.D., Calyxt Scientific Advisory Board Chair and Professor in the Department of Genetics, Cell Biology and Development at the University of Minnesota o Anne Osbourn, Ph.D., Group Leader at the John Innes Center o Elizabeth Sattely, Ph.D., HHMI Investigator and Associate Professor of Chemical Engineering, Stanford University o Paul Bernasconi, Ph.D., Former Global Function Head for Molecular Biology at BASF Biosciences © CALYXT, INC. ALL RIGHTS RESERVED 6 Financial Models for Go-To-Market Strategies POTENTIAL CASH PAYMENTS THROUGHOUT THE DEVELOPMENT CYCLE Go-To-Market Initiation Development Commercial Strategy Trait Development & Upfront fee based on Annual or Milestone- Royalties on commercial Licensing size of opportunity based fees product / value Seed -- -- Revenue from sales Sales Technology Upfront fee based on Royalties on commercial Annual fees Licensing size of opportunity product / value © CALYXT, INC. ALL RIGHTS RESERVED 7 Prioritized Development Pipeline NINE PROJECTS REPRESENT AN $8.8B ADDRESSABLE MARKET Target Commercial Target GTM Partner Addressable Crop Trait Planting Year1 Strategy Status Market1 ($ in millions) Alfalfa Improved digestibility 2021 Trait $65 Wheat High fiber 2023 Trait Prospecting $190 Soybean High oleic, low linolenic (HOLL) 2 2023 Seed Prospecting $7602 Seed Hemp Marketable yield 2023 Prospecting Trait $2,100 Seed Hemp Low THC for fiber, food, & nutraceutical 2024 Prospecting Trait Seed Oat Winter (cold tolerant) 2026 Prospecting $3,600 Trait Seed Soybean Improved HOLL2 2026 Trait Seed Soybean High saturated fat 2026 Prospecting Trait $2,100 Soybean Enhanced protein flavor 2027 Trait We are also negotiating with potential partners with respect to specific opportunities for which development activity would only commence upon reaching an agreement. $8,800 1 See the information on slides 47-52 of Calyxt’s 2020 Virtual Investor Day on November 17, 2020 available on the Company’s website for sources and key assumptions underlying the total addressable market and potential product revenue opportunities, which includes information that was publicly disclosed as of November 17, 2020 and is not being updated as of the date of this presentation. © CALYXT, INC. ALL RIGHTS RESERVED 8 2 The $760 million represents the aggregated value of all HOLL seed projects’ addressable market Fourth Quarter Financial Results Three Months Ended December 31 $ in millions except per share amounts 2020 2019 Revenue $ 13.9 $ 3.8 Gross margin, as reported $ (4.9) $ (1.7) Gross margin (%) (35%) (44%) Gross margin, as adjusted¹ $ (3.9) $ (1.6) Gross margin, as adjusted (%)¹ (28%) (43%) Operating expenses $ 8.1 $ 10.3 Net loss $ (13.4) $ (12.2) Adjusted net loss¹ $ (12.0) $ (12.0) Net loss per share $ (0.37) $ (0.37) Adjusted net loss per share¹ $ (0.33) $ (0.37) Adjusted EBITDA¹ $ (9.8) $ (8.6) ¹ Gross margin, as adjusted and adjusted net loss, net loss per share, and adjusted EBITDA are non-GAAP measures. Reconciliations are provided to gross margin, net loss, and net loss per share, the associated GAAP measures, beginning on page 19 of this presentation. © CALYXT, INC. ALL RIGHTS RESERVED 9 Fourth Quarter Cash Usage Bridge NET CASH USED IN THE FOURTH QUARTER OF 2020 IMPROVED BY $17.6 MI LLI ON COMPARED TO THE FOURTH QUARTER OF 2019 $ in Millions December 31, 2020 cash, cash equivalents, restricted cash,
Load more

Recommended publications
  • 2020 Stanford Bio-X Fellowship Brochure
    STANFORD BIO-X PHD FELLOWSHIPS 2020 Stanford Bio-X Fellows Group Photo 2019 The Stanford Bio-X Graduate Fellowships The mission of the Stanford Bio-X Program is to catalyze discovery by crossing the boundaries between disciplines to bring interdisciplinary solutions, to create new knowl- edge of biological systems, and to benefit human health. Since it was established in 1998, Stanford Bio-X has charted a new approach to life science research by bringing together clinical experts, life scientists, engineers, and others to tackle the complexity of the human body. Currently over 980 Stanford Faculty and over 8,000 students, postdocs, researchers, etc. are affiliated with Stanford Bio-X. The generous support from donors, including the Bowes Foundation, enables the program to remain successful—at any given time, Stanford Bio-X is training at least 60 Ph.D fellows, and Fall 2020 brings 21 new fellows to the program. The Stanford Bio-X Graduate Fellowship Program was started to answer the need for training a new breed of visionary science leaders capable of crossing the bound- aries between disciplines in order to bring novel research endeavors to fruition. Since its inception in 2004, the three-year fellowships, including the Stanford Bio-X Bowes Fellowships and the Bio-X Stanford Interdisciplinary Graduate Fellowships (Bio-X SIGFs), have provided 318 graduate students with awards to pursue interdisciplinary research and to collaborate with multiple mentors, enhancing their potential to gen- erate profound transformative discoveries. Stanford Bio-X Fellows become part of a larger Stanford Bio-X community of learning that encourages their further networking and development.
    [Show full text]
  • Multi-Omic Approaches for Biosynthetic Pathway Prediction in Plants
    Propositions 1. Although guilt-by-association (the principle behind many gene function prediction approaches) promotes “throwing data against the wall to see what sticks”, there is value in interpreting what did not “stick”. (this thesis) 2. To aid data interoperability and re-use, the design of new -omics experiments should always consider the design of previous ones with similar objectives or parameters. (this thesis) 3. Skilled computational scientists make themselves irrelevant for routine tasks, and indispensable for novel ones. 4. Within Academia excess attention is given to the name and prestige of journals, laboratories and authors. 5. The basics of “programming” and “computer science” will soon be seen as analogous to “literacy” and “numeracy”. 6. Children should be taught about life that most adults, if not all, are making it up as they live. Propositions belonging to the thesis, entitled Multi-omics Approaches for Biosynthetic Pathway Prediction in Plants Hernando Suarez Wageningen, 8 February 2021 Multi-omics approaches for biosynthetic pathway prediction in plants Hernando Suarez 2 Thesis committee Promotors Prof. Dr. Ir. D. de Ridder Professor of Bioinformatics Wageningen University & Research Co-promotor Dr. M.H. Medema Assistant Professor of Bioinformatics Wageningen University & Research Other members Prof. Dr. C.S. Testerink, Wageningen University & Research Dr. M.F. Seidl, Utrecht University Dr. S.E. O’Connor, Max Planck Institute of Chemical Ecology, Jena, Germany Dr. R. Cavill, Maastricht University This research was conducted under the auspices of the Graduate School Experimental Plant Sciences 3 Multi-omics approaches for biosynthetic pathway prediction in plants Thesis submitted in fulfilment of the requirements for the degree of doctor at Wageningen University by the authority of the Rector Magnificus, Prof.
    [Show full text]
  • 2016 JGI Secondary Metabolite Abstract Book
    Microbial and Plant Systems Modulated by Secondary Metabolites Meeting May 2–4, 2016 Walnut Creek, California Meeting Abstracts All information current as of April 29, 2016 JGI Contact: Denise Yadon DOE Joint Genome Institute [email protected] The Joint Genome Institute is a user facility of the Department of Energy Office of Science DOE Joint Genome Institute: www.jgi.doe.gov DOE Office of Science: science.energy.gov Agenda Agenda Monday, May 2 (Walnut Creek Marriott) 5:00 – 5:10 PM Opening Remarks Host: Susannah Tringe, JGI 5:10 – 6:00 PM Opening Key Note: Niche adaptation of Julia Vorholt, ETH Zurich the Arabidopsis leaf microbiota 6:00 – 9:00 PM Poster Session and Reception *Refreshments served Tuesday, May 3 (JGI Room 149A) 9:00 – 10:10 AM Overview of the JGI Capabilities Chair: Yasuo Yoshikuni, JGI * Will include morning break & working lunch 9:00 – 9:10 AM Welcome and Introduction Susannah Tringe, JGI *Morning refreshments served 9:10 – 9:25 AM JGI Synthesis Science Yasuo Yoshikuni, JGI 9:25 – 9:40 AM JGI Synthesis Platform Sam Deutsch, JGI 9:40 – 9:55 AM IMG-ABC: A Resource for Biosynthetic Michalis Hadjithomas, JGI Gene Cluster Discovery and Analysis 9:55 – 10:10 AM JGI Metabolomics Trent Northen, JGI 10:10 – 10:30 AM Break 10:30 – 12:05 PM SESSION I: Science from the JGI User Communities 10:30 – 10:35 AM Introduction Yasuo Yoshikuni, JGI 10:35 – 11:05 AM Investigating Plant Terpene Metabolic Philipp Zerbe, Diversity for Pharmaceutical and University of California, Davis Agricultural Applications 11:05 – 11:35 AM Volatile Metabolites
    [Show full text]
  • Division of Organic Chemistry
    ORGN DIVISION OF ORGANIC CHEMISTRY S. Silverman and E. McLaughlin, Program Chairs SUNDAY MORNING Section A Pennsylvania Convention Center 116 New Reactions & Methodology S. M. Silverman, Organizer 8:00 1. Copper catalyzed reductive carbonylation of alkyl iodides. S. Zhao, N.P. Mankad 8:20 2. Sulfenate-anion-catalyzed diastereoselective aziridination of imines. Z. Zheng, P.J. Walsh 8:40 3. Cyanoalkylcopper species in carbon-carbon bond forming reactions. D.L. Silverio 9:00 4. New reactivity enabled by cation-π interactions. P.J. Walsh 9:20 5. Dipolar alkynyl-prins (DAP) cyclization for the rapid construction of complex polycycles. S. Abdul-Rashed, G. Alachouzos, A. Frontier 9:40 6. Subphthalocyanines and perylene-diimide derivatives in organic photovoltaics. L. Chockalingam Kasi Viswanath 10:00 7. Silylated α-aminonitriles for late-stage functionalization. T. Mathew, T. Yamato, S.G. Prakash 10:20 8. Synthesis of differentially substituted diynes via tandem nucleophilic addition/fragmentation pathways. A. Tavakoli, G.B. Dudley 10:40 9. Analogues of Bestmann’s ylide, Ph3P=C=C=O: Syntheses, structures and Lewis acid catalyzed cyclizations with organic substrates. C. Krempner 11:00 10. Diastereoselective alkynylations of β-(Bromo)iminium ions via copper(I) catalysis. S.O. Santana, W. Guan, M.P. Watson 11:20 11. Modular three-component difunctionalization of aryl/cyclohexenyl triflates via arynes and cyclohexynes. S. Cho, Q. Wang 11:40 12. 1,2-aminocyanation of alkenes via distal migration. Y. Kwon, Q. Wang Section B Pennsylvania Convention Center 117 Heterocycles & Aromatics S. M. Silverman, Organizer 8:00 13. Formal [4+2] cycloaddition between alkynes and allene-ynes to generate functionalized toluenes.
    [Show full text]
  • Funding Plant Biology in Hard Times 5 Days by RICHARD DIXON in Austin University of North Texas, Denton Enjoy The
    May/June 2016 • Volume 43, Number 3 p. 7 p. 14 p. 25 ASPB Announces ASPB; Making a 2016 Summer 2016 Awards Difference in 2015 Undergraduate Research Fellows THE NEWSLETTER OF THE AMERICAN SOCIETY OF PLANT BIOLOGISTS President’s Letter Funding Plant Biology in Hard Times 5 Days BY RICHARD DIXON in Austin University of North Texas, Denton Enjoy the ’m not sure that I know When I moved to the United Outdoors any research scientist who States in 1988 and started to Iwouldn’t claim that fund- participate on federal grant ing is tight these days. With panels, I was impressed by It’s All About historically low success rates their relatively broad remit, the Food at federal agencies, industry as the system from which I consolidating and pulling had just moved had recently back from supporting science become more difficult to Music Lover’s in the public sector, and state maneuver—only Arabidopsis funding for public universities one year, something else the Paradise no longer what it used to be, next. Although discipline times are hard. Several of the specific, the programs at federal programs that have Rick Dixon USDA and NSF did not spec- Annual been staples for funding plant ify more circumscribed areas biology in the past now have success rates but in large part allocated funding based on Party of less than 10%; this seems a far cry from the best science. Furthermore, most of the the days when I was on panels that funded grants in those days were single investigator around 35% of proposals, some as merit- grants, and if you made good progress, you President’s based awards in which a proposal from a could hopefully count on continued fund- Symposium lab that had shown a strong track record in ing that would see you through your tenure the past would, rightly or wrongly, undergo evaluation and beyond.
    [Show full text]
  • Stanford University E N G I N E E R I N G Chemical Engineering Stanford, CA 94305-5025
    CHAITAN KHOSLA School of Engineering STANFORD Wells H. Hauser and Harold M. Petiprin Professor Keck, Room 337 CHEMI CAL Chair, Department of Stanford University E n g i n e e r i n G Chemical Engineering Stanford, CA 94305-5025 Fall 2010 Dear Chemical Engineering Alumni and Friends, As the new academic year begins, I’d like to tell you about some of the significant events in the Stanford Department of Chemical Engineering over the past year. Our 50th Birthday Party On May 11, at this year’s Mason Lectures, we celebrated the 50th anniversary of the founding of the Stanford Department of Chemical Engineering. And what a celebration it was! Special thanks to Gerry Fuller, Pam Juanes, and a core group of alumni including John Richardson, Eric Lutkin, Carol Fisher, and Lisa Hwang for making the event a huge success. What started as a dream in the brain of the late Professor David Mason half a century ago has now evolved into a department with 15 active faculty, approximately 75 undergraduate majors, more than 100 graduate students, and more than 20 postdoctoral researchers. Last year alone, students and faculty in the department collectively published more than 100 peer-reviewed papers in the primary literature. More than a dozen U.S. patents were awarded to researchers in the department. And somehow, if you ask any student or faculty member, they’ll shrug their shoulders and say that we’re only just getting started. Much has changed in the past 50 years, but some things remain the same. Foremost among the constants are our shared passion for teaching and learning and our unshakeable confidence that as long as Stanford chemical engineers remain well schooled in the foundational sciences of physics, chemistry, and biology, and as long as they are adequately introduced to the awesome conceptual and practical power of the preparative, analytical, and modeling tools that we call chemical engineering, good things will continue to happen.
    [Show full text]